The global cancer biomarkers market is expected to exceed US$ 157.37 billion by 2022, registering a compound annual growth rate (CAGR) of 13.3% during the forecast period. The increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, and low cost of clinical trials in developing countries are expected to drive the market. In addition, the high prevalence of cancer and new initiatives for biomarker research are expected to fuel the growth of the market. However, the high capital investments and low cost-benefit ratio, poorly suited government regulations and reimbursement policies, and technical issues related to sample collection and storage are restricting the growth of the market.
In this report, the global cancer biomarkers market is segmented by cancer type, application, profiling technology, biomolecules, and region. The market on the basis of cancer type is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, and others. On the basis of application, the market is segmented into diagnostics, drug discovery & development, prognostics, risk assessment, and others. The market by profiling technology is segmented into Omic technology, imaging technology, immunoassays, and cytogenetics-based tests. On the basis of biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers.
The global cancer biomarkers market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional cancer biomarkers market and analyzes the variations in the growth of the industry in certain regions.
A glimpse of the report structure is provided in the report description available on the website.
F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V., and Genomic Health, Inc. are the most active players in the cancer biomarkers market.
This report covers the cancer biomarkers market, in terms of value, and forecasts the market size till 2022. In addition, the report identifies key growth segments and opportunities in the industry. This report also covers detailed competitive outlook including the share and company profiles of the key players in the global market. Company profile includes company summary, financial summary, business strategy and planning, SWOT analysis, and current developments.
The deep-dive study on the cancer biomarkers market will help customers with the identification of new market opportunities and targeted promotional plans.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com